SCHEDULE 13G/A: BlackRock Discloses 5.1% Stake in INSMED INC

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in INSMED INC as of June 30, 2025, primarily for investment purposes.

Summary

• BlackRock, Inc. reported beneficial ownership of 9,729,641 shares of INSMED INC Common Stock.
• This stake represents 5.1% of the total outstanding class of securities.
• BlackRock holds sole voting power over 9,327,553 shares and sole dispositive power over 9,729,641 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of INSMED INC.
• This filing is an Amendment No. 12 to the Schedule 13G, with the event date requiring the filing being June 30, 2025.
• BlackRock Fund Managers Ltd is identified as an entity within BlackRock that beneficially owns 5% or greater of the outstanding shares of INSMED INC.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of beneficial ownership by a major institutional investor, BlackRock, Inc. The maintenance of a significant 5.1% stake, held in the ordinary course of business, suggests continued institutional confidence in INSMED INC.

Positives

• BlackRock, Inc., a major institutional investor, maintains a significant 5.1% beneficial ownership stake in INSMED INC, indicating continued institutional confidence.
• The shares are held in the ordinary course of business, suggesting a passive, long-term investment perspective rather than an activist intent.

Future Outlook

No forward-looking statements or guidance regarding INSMED INC's operations or financial performance are provided in this ownership disclosure.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11." (Statement from BlackRock, Inc. regarding the purpose of their holdings)

Industry Context

This filing is a routine disclosure of an institutional investor's equity stake, reflecting BlackRock's ongoing portfolio management activities. It indicates continued institutional interest in INSMED INC, which is common for publicly traded companies with established market presence.

Comparison to Industry Standards

• BlackRock's aggregate beneficial ownership of 5.1% in INSMED INC is a significant institutional stake, consistent with the portfolio management strategies of large asset managers.
• The distribution of this ownership across various BlackRock subsidiaries, including BlackRock Fund Managers Ltd holding 5% or more, reflects standard practices for diversified investment firms managing assets across multiple funds and client mandates, similar to how other major asset managers like Vanguard or State Street manage their passive and active equity holdings.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holder's stake, potentially signaling confidence in the company.
• Management: Awareness of a large, passive institutional investor holding a substantial stake.

Key Dates

Keywords

INSMED INC, BlackRock, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake, SEC filing